AusperBio Announces 70% Functional Cure Rate with AHB-137 in Treatment-Naïve Chronic Hepatitis B Patients at EASL 2026
May 27, 2026 17:16
CST Updated
May 28, 02:29
AusperBio
Biological Vaccine and Nucleic Acid Drug Developer